Journal
BIOMATERIALS
Volume 33, Issue 33, Pages 8625-8631Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.08.006
Keywords
Main-chain imidazolium oligomer; Broad spectrum antimicrobial agent; Drug-resistant microbials; Haemoconipatible; High in vivo efficacy
Funding
- Institute of Bioengineering and Nanotechnology, Biomedical Research Council, Exploit Technologies Pte Ltd, Agency for Science, Technology and Research
- epidemiology, prevention and control of major infectious diseases on the scene, Mega-projects of Science Research for the 12th Five-Year Plan of China [2011ZX10004-901]
- National Natural Science Foundation of prevention and control of major infectious diseases on the scene, Mega-projects of Science Research for the 12th Five-Year Plan of China [2011ZX10004-901]
- National Natural Science Foundation of China [81070285]
Ask authors/readers for more resources
Human health has been challenged by multi-drug-resistant microorganisms for several decades. Herein, we have developed a main-chain imidazolium oligomer (IBN-1) material to combat broad spectrum of pathogenic strains, including drug-resistant Klebsiella pneumoniae, Vancomycin-resistant enterococcus, Methicillin-resistant Staphylococcus aureus and fluconazole-resistant yeast Cryptococcus neoformans, while displaying minimal hemolysis (HC50/MIC values over 3000) and a very high therapeutic index of 37 for killing S. aureus under inflammatory conditions in vivo. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
